4/A: Citius Oncology Director Holubiak Amends Form 4 to Correct Stock Option Holdings

Myron Z. Holubiak, a director at Citius Oncology, filed an amended Form 4 to correct the reported amount of stock options held following a merger transaction.

Summary

• Myron Z. Holubiak, a director of Citius Oncology, Inc. filed an amended Form 4 with the SEC.
• The amendment corrects the amount of option shares held by Holubiak.
• The original transaction date was August 12, 2024, and the original filing date was August 14, 2024.
• Holubiak was granted 1,500,000 stock options with an exercise price of $2.15 on August 12, 2024.
• These options vest over three years, starting July 5, 2023, with monthly vesting for the first year and annual vesting for the subsequent two years, contingent on continuous service.
• The options were initially issued by Citius Oncology Sub, Inc. and assumed by Citius Oncology, Inc. following a merger on August 12, 2024.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing. The correction of information is a positive sign of transparency.

Positives

• The director's holdings are being accurately reported.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency in the market.

Stakeholder Impact

• Shareholders benefit from accurate reporting of insider holdings.

Key Dates